Ionis Pharmaceuticals (MEX:IONS) Cyclically Adjusted Revenue per Share: MXN92.66 (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
67 GF Score
Price MXN1,150.00
GF Value MXN716.67
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share?

Ionis Pharmaceuticals MEX:IONS 67 Cyclically Adjusted Revenue per Share is MXN92.66 as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 67/100 and a GF Value™ of MXN716.67. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was MXN26.916. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN92.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ionis Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ionis Pharmaceuticals was 23.20% per year. The lowest was -5.50% per year. And the median was 6.65% per year.

As of today (2026-07-08), Ionis Pharmaceuticals's current stock price is MXN1150.00. Ionis Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN92.66. Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 12.41.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ionis Pharmaceuticals was 38.42. The lowest was 4.90. And the median was 13.30.


Ionis Pharmaceuticals  (MEX:IONS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1150.00/92.66
=12.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ionis Pharmaceuticals was 38.42. The lowest was 4.90. And the median was 13.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.74 105.68 73.91 115.83 84.89

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.59 93.34 101.61 84.89 92.66

MEX:IONS vs EXEL, BBIO, AXSM: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


MEX:IONS
67GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=26.916/330.2130*330.2130
=26.916

Current CPI (Mar. 2026) = 330.2130.

Ionis Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 5.890 241.018 8.070
201609 17.384 241.428 23.777
201612 31.687 241.432 43.339
201703 17.447 243.801 23.631
201706 16.368 244.955 22.065
201709 17.264 246.819 23.097
201712 25.985 246.524 34.806
201803 20.935 249.554 27.701
201806 17.976 251.989 23.556
201809 19.801 252.439 25.901
201812 26.068 251.233 34.263
201903 40.734 254.202 52.914
201906 22.437 256.143 28.925
201909 23.113 256.759 29.725
201912 50.549 256.974 64.956
202003 22.429 258.115 28.694
202006 24.107 257.797 30.879
202009 25.312 260.280 32.113
202012 41.257 260.474 52.303
202103 16.206 264.877 20.203
202106 17.758 271.696 21.583
202109 19.390 274.310 23.342
202112 63.921 278.802 75.708
202203 19.956 287.504 22.920
202206 18.983 296.311 21.155
202209 22.640 296.808 25.188
202212 20.847 296.797 23.194
202303 16.483 301.836 18.033
202306 22.573 305.109 24.430
202309 17.527 307.789 18.804
202312 38.357 306.746 41.291
202403 13.627 312.332 14.407
202406 28.273 314.175 29.716
202409 17.732 315.301 18.571
202412 29.918 315.605 31.303
202503 16.963 319.799 17.515
202506 46.683 322.561 47.790
202509 17.994 324.800 18.294
202512 22.545 324.054 22.973
202603 26.916 330.213 26.916

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN92.66 mean?
Ionis Pharmaceuticals (MEX:IONS) has a Cyclically Adjusted Revenue per Share of MXN92.66 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Ionis Pharmaceuticals' current Cyclically Adjusted Revenue per Share is MXN92.66. Overall, Ionis Pharmaceuticals has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to EXEL and BBIO?
Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share of MXN92.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cyclically Adjusted Revenue per Share is MXN92.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Cyclically Adjusted Revenue per Share of MXN92.66. The stock's GF Value™ is MXN716.67, compared to a current price of MXN1,150.00 — trading 60.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN92.66. Ionis Pharmaceuticals' overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Cyclically Adjusted Revenue per Share is MXN92.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 60.5% above its estimated GF Value™ of MXN716.67.

Key valuation signals for MEX:IONS:

  • Cyclically Adjusted Revenue per Share: MXN92.66
  • GF Value™: MXN716.67 vs. price of MXN1,150.00 (60.5% above fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
67GF Score

Get the complete analysis for MEX:IONS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN716.67
GF Value